{"brief_title": "TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer", "brief_summary": "The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.", "condition": ["Ovarian Neoplasms"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["TLK286 HCl for injection", "topotecan hydrochloride for injection", "doxorubicin HCl liposome injection"], "criteria": "Inclusion criteria include: - Considered platinum refractory or resistant according to standard criteria - Progressed during or following completion of one second-line treatment with Doxil/Caelyx or Hycamtin - Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer - Measurable disease according to RECIST criteria with documented tumor progression Exclusion criteria include: - Treatment with second-line chemotherapy other than Doxil/Caelyx or Hycamtin - History of whole pelvis radiation therapy within 12 months of enrollment - Clinically significant cardiac disease - Evidence of gross hematuria at the time of study entry - Any signs of intestinal obstruction interfering with nutrition at the time of study entry - Pregnant or lactating women", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "ovary", "mesh_term": ["Ovarian Neoplasms", "Doxorubicin", "Liposomal doxorubicin", "Topotecan"], "id": "NCT00057720"}